Generation Bio, a leading biotechnology company focused on developing genetic medicines for rare and prevalent diseases, has announced that Geoff McDonough, M.D., the company’s president and CEO, will participate in a fireside chat at the upcoming Canaccord Genuity 44th Annual Growth Conference. The conference will take place on Tuesday, August 13th, 2024 at 2:30 p.m. ET in Boston.
During the fireside chat, Dr. McDonough will discuss Generation Bio’s innovative approach to genetic medicine and its potential to provide durable and redosable treatments for millions of patients worldwide. The company is developing two distinct platforms: a cell-targeted lipid nanoparticle (ctLNP) delivery system and a novel immune-quiet DNA (iqDNA) cargo. These platforms aim to extend the reach of genetic medicine to more people living with various diseases.
Investors and interested individuals can access a live webcast of the presentation on the investor section of Generation Bio’s website at investors.generationbio.com. A replay of the event will also be available on the website for 30 days following the conference.
Generation Bio is dedicated to advancing non-viral genetic medicines and aims to make a positive impact on the lives of patients with rare and prevalent diseases. To learn more about Generation Bio and its mission, visit www.generationbio.com.